US20160243292A1 - Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof - Google Patents
Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof Download PDFInfo
- Publication number
- US20160243292A1 US20160243292A1 US15/147,712 US201615147712A US2016243292A1 US 20160243292 A1 US20160243292 A1 US 20160243292A1 US 201615147712 A US201615147712 A US 201615147712A US 2016243292 A1 US2016243292 A1 US 2016243292A1
- Authority
- US
- United States
- Prior art keywords
- absorbable
- radiopaque
- medical device
- group
- aliphatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
- C08G18/46—Polycondensates having carboxylic or carbonic ester groups in the main chain having heteroatoms other than oxygen
- C08G18/4607—Polycondensates having carboxylic or carbonic ester groups in the main chain having heteroatoms other than oxygen having halogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/18—Materials at least partially X-ray or laser opaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/73—Polyisocyanates or polyisothiocyanates acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
- C08G63/682—Polyesters containing atoms other than carbon, hydrogen and oxygen containing halogens
- C08G63/6822—Polyesters containing atoms other than carbon, hydrogen and oxygen containing halogens derived from hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/02—Aliphatic polycarbonates
- C08G64/0208—Aliphatic polycarbonates saturated
- C08G64/0225—Aliphatic polycarbonates saturated containing atoms other than carbon, hydrogen or oxygen
- C08G64/0233—Aliphatic polycarbonates saturated containing atoms other than carbon, hydrogen or oxygen containing halogens
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D167/00—Coating compositions based on polyesters obtained by reactions forming a carboxylic ester link in the main chain; Coating compositions based on derivatives of such polymers
- C09D167/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D169/00—Coating compositions based on polycarbonates; Coating compositions based on derivatives of polycarbonates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
- Y10T428/139—Open-ended, self-supporting conduit, cylinder, or tube-type article
Definitions
- the present invention is directed to iodine-bearing, absorbable polymeric compositions and inorganic, iodide-containing absorbable polymers and applications thereof in preparing absorbable radiopaque, melt-extruded monofilaments, electrostatically spun microfibers, surface coatings, and radiographic markers, which can, in turn, be used individually or in combination for assembling radiographically detectable medical devices and controlled release drug delivery systems.
- radiopacity to medical devices and polymeric materials therefor was limited to incorporating sufficient amounts of radiopaque, insoluble inorganic microparticles of heavy metal salts or oxides, as in the case of the use of barium sulfate in polymethyl methacrylate bone cement (Damian & Shalaby, U.S. Pat. No. 5,795,922) and several types of non-absorbable, non-crystalline polymeric materials such as those based on silicones and polyurethanes.
- this invention is directed to (1) the preparation of new, 80-100% aliphatic, absorbable, crystalline iodinated polymers for use as coatings and radiographic markers for medical devices; (2) the preparation of melt-extrudable hybrid composites into microfilament, monofilament, and multifilament yams of water-soluble inorganic iodide salt and absorbable copolyester; (3) devices made of the above-noted radiopaque monofilament and multifilament yarns and radiopaque coatings; and (4) devices analogous to the above-noted ones comprising a radioactive iodine isotope (e.g., iodine-131 or 123) for use as pharmacokinetic markers and in radiation therapy.
- a radioactive iodine isotope e.g., iodine-131 or 123
- the present invention is directed to a radiopaque, iodinated, crystalline, aliphatic, absorbable polyester having a molecular weight exceeding 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa and a heat of fusion of at least 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, wherein the polyester is the reaction product of an iodohydroxylic or iodo-substituted amine initiator, and at least one monomer selected from the group consisting of l-lactide, glycolide, trimethylene carbonate, p-dioxanone, 1,5-dioxepan-2-one, ⁇ -caprolactone, and a morpholinedione under typical ring-opening polymerization conditions, using an organometallics catalyst.
- a specific aspect of this invention deals with a radiopaque, iodinated, crystalline, 80-100% aliphatic, absorbable polyester having a molecular weight exceeding 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa, and a heat of fusion of at least 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, in the form of a radiopaque coating, part of a higher molecular coating, radiographically detectable marker, or a component in at least one medical device, wherein the at least one medical device is selected from the group consisting of an absorbable/disintegratable urinogenital stent, an absorbable endovascular stent, absorbable diagnostic device, and absorbable barrier film to protect surrounding tissue from low level radiation associated with Brachy therapy, or treatment for abdominal and ovarian cancer, and an absorbable diagnostic device.
- Another specific aspect of this invention deals with a radiopaque, iodinated, crystalline, 80-100% aliphatic, absorbable polyester having a molecular weight exceeding 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa, and a heat of fusion of at least 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, wherein the polyester is the reaction product of an iodohydroxylic initiator, and at least one monomer selected from the group consisting of l-lactide, glycolide, trimethylene carbonate, p-dioxanone, 1,5-dioxepan-2-one, ⁇ -caprolactone, and a morpholinedione under typical ring-opening polymerization conditions, using an organometallics catalyst, and wherein the polyester chains are covalently interlinked with a urethane group to increase
- the interlinked chains are the reaction product of a hydroxy-terminated iodinated polyester and an aliphatic diisocyanate selected from the group consisting of 1,6-hexane-diisocyanate, 1,4-bis(methylene isocyanato) cyclohexane, 1,6-cyclohexane diisocyanate, 1,4-tetramethylene diisocyanate, and lysine diisocyanate and the respective products can be used in the form of a radiopaque coating, part of a higher molecular coating, radiographically detectable marker, or a component in at least one medical device, wherein the at least one medical device is selected from the group consisting of an absorbable disintegratable urinogenital stent, an absorbable endovascular stent, an absorbable device for treating aneurysm, a device for treating prostatic cancer, and an absorbable diagnostic device.
- an absorbable disintegratable urinogenital stent an absorbable endo
- a clinically important aspect of this invention deals with a radiopaque, iodinated, crystalline, 80-100% aliphatic, absorbable polyester having a molecular weight exceeding 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa, and a heat of fusion of at least 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, wherein the iodine component is iodine-127.
- the simple iodinated products and their radioactive counterparts are suitable for use in therapeutic, site-specific applications.
- Another major aspect of this invention deals with a radiopaque, absorbable composite of at least one type of inorganic iodo-compound micro-/nanoparticles dispersed or solubilized in an organic absorbable crystalline matrix having a molecular weight of at least 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa, and a heat of fusion exceeding 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, wherein the at least one type of inorganic iodo-compound micro-/nanoparticles represent 10 to 70 percent of the total mass of the composite, wherein the organic absorbable crystalline matrix is (1) an absorbable polyester derived from at least one cyclic monomer selected from the group consisting of l-lactide, glycolide, trimethylene carbonate, p-dioxanone, 1,5-dioxe
- a second clinically important aspect of this invention deals with a radiopaque, absorbable composite of at least one type of inorganic iodo-compound micro-/nanoparticles dispersed or solubilized in an organic absorbable crystalline matrix having a molecular weight of at least 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa, and a heat of fusion exceeding 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, wherein said product is in the form of a coating, part of a higher molecular weight coating, radiographically detectable marker, or component of at least one medical device, and wherein the at least one medical device is selected from the group consisting of an absorbable/disintegratable urinogenital stent, absorbable endovascular stent, an absorbable device for treating aneurysm, a device for treating prostatic,
- a technologically important aspect of this invention deals with all compositions described herein, processed into at least one fibrous form selected from the group consisting of electrospun non-woven microfibers, melt-extruded monofilament and multifilament yarns, melt-extruded tubes, and catheters.
- the present invention is directed to totally absorbable/dissolvable radiopaque compositions for use in pharmaceutical and biomedical applications, wherein the radiopacity is due to the presence of an iodine or bromine atom that is covalently linked to the molecular chain of an absorbable polymer and/or the presence of at least one water-soluble micro-/nanoparticulate iodide or bromide salt selected from those comprising an alkaline or alkaline earth metal atom, preferably sodium iodide, potassium iodide, and magnesium iodide.
- the absorbable polymers comprising iodine or bromine atom-bearing chains, there can be more than one of such atoms per molecular chain.
- the respective absorbable chains may comprise at least one type of ester linkage.
- Other chemical linkages can be present in those chains and can be selected from the group consisting of an aliphatic carbonate, acyclic carbonate, cycloaliphatic urethane, acyclic aliphatic urethane, cycloaliphatic carbonate, aliphatic ether, and aliphatic anhydride.
- Typical applications of iodine-bearing absorbable polymers include: (1) surface coatings for catheters, particularly those used percutaneously; (2) absorbable constructs for site-specific diagnostic applications; (3) components of absorbable/disintegratable endovascular and urinogenital stents; (4) catheters for deploying radioactive compositions for treating cancer as in the case of iodine-131 (or 123) in the treatment of prostate, lung, intestinal or ovarian cancers; (5) dosage forms for the controlled delivery of iodide in the treatment of thyroid glands and particularly in the case of accidental exposure to radioactive iodine; (6) components of an absorbable device or pharmaceutical product to monitor its pharmacokinetics using iodine-127, 123 or 131; and (7) barrier film to protect surrounding tissues during Brachy therapy and similar radiotherapies as in the treatment of ovarian and abdominal cancers.
- iodine-bearing absorbable polymers referred to herein as “iodinated polymers”
- the radiopaque lactide/glycolide copolymer initiated with 3-iodo-1-propanol (3.05 ⁇ 10 ⁇ 3 mol, 50.1 grams), was added to a flame-dried reaction kettle fitted with a mechanical stirrer, a distillation neck and a collection flask.
- the polymer was dissolved in dichloromethane (0.5 g/ml) and mixed thoroughly with the mechanical stirrer at room temperature. Then 1,6-diisocyanatohexane (I.527 ⁇ 10 ⁇ 3 moles, 0.257 grams) was added to the reaction (1 mole of 1,6-diisocyanatohexane per 2 moles polymer) and the temperature was increased to 150° C.
- Films were prepared by a solvent-casting technique by first dissolving PI-1 in a mixture of 1:1 dichloromethane:chloroform at a concentration of 5-w/v%. The polymer solution was transferred to a glass container to allow solvent evaporation, resulting in a film (PI-1F1) of 0.2 mm thickness.
- Preparation of Films from PI-1 containing 10% NaI was performed by dissolving 2.7 g PI-1 and 0.3 g NaI in 60 mL of trifluoroethanol. The dissolved solution was transferred to a glass container to allow solvent evaporation, resulting in a film (PI-1F2) of 0.2 mm thickness.
- Radiopacity of both films was verified using a Tingle model 325 M Veterinary X-ray unit with an EKLIN model EDR5-MKV processor.
- Electrospinning was accomplished on an electrospinning unit constructed in-house from a solution containing approximately 25-w/v% PI-1 in 1:1 dichloromethane:chloroform. Electrospinning was conducted using the following conditions: +5.6 kV charge at needle tip, ⁇ 8.7 kV charge at collection rod, +5 kV at directional rings, 18 G blunt end needle, 0.25 mL/min flow rate, and 18 cm tip-to-collector distance.
- the electrospun fabric was comprised of microfibers having an average diameter of 5 micron.
Abstract
Radiopaque, iodinated, absorbable polyesters, polyester urethanes, and polyether-ester-urethanes with and without inorganic iodide micro-/nanoparticles dispersed or solubilized therein, and composite inorganic iodide micro-/nanoparticles in an absorbable polyester, polyester-urethane, polyester-ester, or polyether-ester urethane matrix are employed in medical devices and therapeutic compositions.
Description
- The present application claims the benefit of prior provisional application, U.S. Ser. No. 61/211,857 filed Apr. 3, 2009.
- The present invention is directed to iodine-bearing, absorbable polymeric compositions and inorganic, iodide-containing absorbable polymers and applications thereof in preparing absorbable radiopaque, melt-extruded monofilaments, electrostatically spun microfibers, surface coatings, and radiographic markers, which can, in turn, be used individually or in combination for assembling radiographically detectable medical devices and controlled release drug delivery systems.
- Until recently, imparting radiopacity to medical devices and polymeric materials therefor was limited to incorporating sufficient amounts of radiopaque, insoluble inorganic microparticles of heavy metal salts or oxides, as in the case of the use of barium sulfate in polymethyl methacrylate bone cement (Damian & Shalaby, U.S. Pat. No. 5,795,922) and several types of non-absorbable, non-crystalline polymeric materials such as those based on silicones and polyurethanes. In recent years, the concept of producing inorganic-organic hybrid fibers comprising insoluble radiopaque, inorganic microparticles and crystalline polymeric components was used by one of the present inventors and coworkers to produce medical devices in order to (1) impart radiopacity in melt-spun monofilaments (U.S. Pat. No. 7,465,489 and U.S. patent application Ser. No. 11/880,993); (2) impart radiopacity in electrostatically spun microfibers (U.S. patent application Ser. No. 11/599,695); and (3) not only impart radiopacity but also contribute to a timely disintegration/absorption of a load-bearing component in an absorbable/disintegratable ureteral stent (PCT Application Serial No. 06/03619 and U.S. patent application Ser. No. 11/346,117). Meanwhile, there has been some interest in preparing iodine- bearing, non-crystalline materials, including absorbable polymers. Most relevant to the instant invention are those which entailed the preparation of polymers with the iodine atom attached to an aromatic side group in the polymer chains (U.S. Pat. No. 6,475,477). To date, the lack of interest in developing or even exploring iodine-containing crystalline, aliphatic polymers of commercial interest in the medical industry is not surprising. This is because of the perceived limitations associated with the conditions used in preparing those polymers or iodide-containing radiopaque polymer blends, which can compromise the stability of the iodine-bearing additive or intermediates. This, and the lack of crystalline absorbable polymers useful for use in preparing radiopaque medical devices and coatings as well as radiographic markers by virtue of having sufficient amounts of iodine-containing species therein, provided an incentive to pursue the study, subject of the instant invention. Accordingly, this invention is directed to (1) the preparation of new, 80-100% aliphatic, absorbable, crystalline iodinated polymers for use as coatings and radiographic markers for medical devices; (2) the preparation of melt-extrudable hybrid composites into microfilament, monofilament, and multifilament yams of water-soluble inorganic iodide salt and absorbable copolyester; (3) devices made of the above-noted radiopaque monofilament and multifilament yarns and radiopaque coatings; and (4) devices analogous to the above-noted ones comprising a radioactive iodine isotope (e.g., iodine-131 or 123) for use as pharmacokinetic markers and in radiation therapy.
- Accordingly, the present invention is directed to a radiopaque, iodinated, crystalline, aliphatic, absorbable polyester having a molecular weight exceeding 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa and a heat of fusion of at least 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, wherein the polyester is the reaction product of an iodohydroxylic or iodo-substituted amine initiator, and at least one monomer selected from the group consisting of l-lactide, glycolide, trimethylene carbonate, p-dioxanone, 1,5-dioxepan-2-one, ε-caprolactone, and a morpholinedione under typical ring-opening polymerization conditions, using an organometallics catalyst.
- A specific aspect of this invention deals with a radiopaque, iodinated, crystalline, 80-100% aliphatic, absorbable polyester having a molecular weight exceeding 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa, and a heat of fusion of at least 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, in the form of a radiopaque coating, part of a higher molecular coating, radiographically detectable marker, or a component in at least one medical device, wherein the at least one medical device is selected from the group consisting of an absorbable/disintegratable urinogenital stent, an absorbable endovascular stent, absorbable diagnostic device, and absorbable barrier film to protect surrounding tissue from low level radiation associated with Brachy therapy, or treatment for abdominal and ovarian cancer, and an absorbable diagnostic device.
- Another specific aspect of this invention deals with a radiopaque, iodinated, crystalline, 80-100% aliphatic, absorbable polyester having a molecular weight exceeding 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa, and a heat of fusion of at least 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, wherein the polyester is the reaction product of an iodohydroxylic initiator, and at least one monomer selected from the group consisting of l-lactide, glycolide, trimethylene carbonate, p-dioxanone, 1,5-dioxepan-2-one, ε-caprolactone, and a morpholinedione under typical ring-opening polymerization conditions, using an organometallics catalyst, and wherein the polyester chains are covalently interlinked with a urethane group to increase its molecular weight to a value exceeding 8 kDa. In effect, the interlinked chains are the reaction product of a hydroxy-terminated iodinated polyester and an aliphatic diisocyanate selected from the group consisting of 1,6-hexane-diisocyanate, 1,4-bis(methylene isocyanato) cyclohexane, 1,6-cyclohexane diisocyanate, 1,4-tetramethylene diisocyanate, and lysine diisocyanate and the respective products can be used in the form of a radiopaque coating, part of a higher molecular coating, radiographically detectable marker, or a component in at least one medical device, wherein the at least one medical device is selected from the group consisting of an absorbable disintegratable urinogenital stent, an absorbable endovascular stent, an absorbable device for treating aneurysm, a device for treating prostatic cancer, and an absorbable diagnostic device.
- A clinically important aspect of this invention deals with a radiopaque, iodinated, crystalline, 80-100% aliphatic, absorbable polyester having a molecular weight exceeding 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa, and a heat of fusion of at least 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, wherein the iodine component is iodine-127. Collectively, the simple iodinated products and their radioactive counterparts (using iodine 123 or 131) are suitable for use in therapeutic, site-specific applications.
- Another major aspect of this invention deals with a radiopaque, absorbable composite of at least one type of inorganic iodo-compound micro-/nanoparticles dispersed or solubilized in an organic absorbable crystalline matrix having a molecular weight of at least 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa, and a heat of fusion exceeding 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, wherein the at least one type of inorganic iodo-compound micro-/nanoparticles represent 10 to 70 percent of the total mass of the composite, wherein the organic absorbable crystalline matrix is (1) an absorbable polyester derived from at least one cyclic monomer selected from the group consisting of l-lactide, glycolide, trimethylene carbonate, p-dioxanone, 1,5-dioxepan-2-one, ε-caprolactone, and a morpholinedione, and wherein the organic absorbable crystalline matrix is selected from the reaction product of an iodohydroxylic initiator, and at least one monomer selected from the group consisting of l-lactide, glycolide, trimethylene carbonate, p-dioxanone, 1,5-dioxepan-2-one, ε-caprolactone, and a morpholinedione under typical ring-opening polymerization conditions, using an organometallics catalyst; and (2) the reaction product from item 1 covalently interlinked with a urethane group to increase its molecular weight to a value exceeding 8 kDa-the interlinking can be achieved using an aliphatic diisocyanate selected from the group consisting of 1,6-hexane-diisocyanate, 1,4-bis(methylene isocyanato)cyclohexane, 1,6-cyclohexane diisocyanate, 1,4-tetramethylene diisocyanate, and lysine diisocyanate.
- A second clinically important aspect of this invention deals with a radiopaque, absorbable composite of at least one type of inorganic iodo-compound micro-/nanoparticles dispersed or solubilized in an organic absorbable crystalline matrix having a molecular weight of at least 5 kDa, preferably exceeding 15 kDa, more preferably exceeding 25 kDa, most preferably exceeding 50 kDa, and a heat of fusion exceeding 10 J/g, preferably at least 20 J/g, more preferably at least 30 J/g, most preferably at least 40 J/g, wherein said product is in the form of a coating, part of a higher molecular weight coating, radiographically detectable marker, or component of at least one medical device, and wherein the at least one medical device is selected from the group consisting of an absorbable/disintegratable urinogenital stent, absorbable endovascular stent, an absorbable device for treating aneurysm, a device for treating prostatic, lung (Brachy therapy), ovarian or intestinal cancers, and an absorbable diagnostic device, and further wherein the iodo-compound comprises iodine-127. Collectively, these composite products and their radioactive counterparts are suitable for use in therapeutic, site-specific applications.
- A technologically important aspect of this invention deals with all compositions described herein, processed into at least one fibrous form selected from the group consisting of electrospun non-woven microfibers, melt-extruded monofilament and multifilament yarns, melt-extruded tubes, and catheters.
- Generally, the present invention is directed to totally absorbable/dissolvable radiopaque compositions for use in pharmaceutical and biomedical applications, wherein the radiopacity is due to the presence of an iodine or bromine atom that is covalently linked to the molecular chain of an absorbable polymer and/or the presence of at least one water-soluble micro-/nanoparticulate iodide or bromide salt selected from those comprising an alkaline or alkaline earth metal atom, preferably sodium iodide, potassium iodide, and magnesium iodide. For the absorbable polymers comprising iodine or bromine atom-bearing chains, there can be more than one of such atoms per molecular chain. The respective absorbable chains may comprise at least one type of ester linkage. Other chemical linkages can be present in those chains and can be selected from the group consisting of an aliphatic carbonate, acyclic carbonate, cycloaliphatic urethane, acyclic aliphatic urethane, cycloaliphatic carbonate, aliphatic ether, and aliphatic anhydride.
- Typical applications of iodine-bearing absorbable polymers (referred to herein as “iodinated polymers”) and/or soluble iodide micro-/nanoparticles include: (1) surface coatings for catheters, particularly those used percutaneously; (2) absorbable constructs for site-specific diagnostic applications; (3) components of absorbable/disintegratable endovascular and urinogenital stents; (4) catheters for deploying radioactive compositions for treating cancer as in the case of iodine-131 (or 123) in the treatment of prostate, lung, intestinal or ovarian cancers; (5) dosage forms for the controlled delivery of iodide in the treatment of thyroid glands and particularly in the case of accidental exposure to radioactive iodine; (6) components of an absorbable device or pharmaceutical product to monitor its pharmacokinetics using iodine-127, 123 or 131; and (7) barrier film to protect surrounding tissues during Brachy therapy and similar radiotherapies as in the treatment of ovarian and abdominal cancers.
- Technologically and clinically important aspects of the instant invention deal with (1) the production of hybrid composites by melt-processing or solution casting of water-soluble inorganic radiopaque iodide salt dispersed in an absorbable thermoplastic polyester, polyether-ester, segmented copolyester, segmented polyether-ester, segmented polyester-urethane, and polyether- ester urethane; (2) the use of at least one of the hybrid composites in item 1 in at least one type of controlled drug release system selected from the group consisting of implantable monofilaments, microspheres, solid-suspensions, and viscous polymeric liquids; (3) the extrusion of at least one composite of item 1 into microfilament, monofilament, multifilament yams and films, which can be used in several applications including the construction of surgical sutures, endovascular stents, perivascular wraps, hemostatic devices, blocking devices, retraction tapes, and endovascular devices for treating aneurysms; (4) electrostatic spinning of solutions of composites in item 1 into non-woven micro-/nano-fibrous fabrics or constructs which can be used as pledgets and components thereof: hemostatic felts, drug delivery systems, and antimicrobial cuffs for catheters; (5) the preparation of surface coatings to enhance or impart radiopacity of any of the surgical devices noted in items 1-4; and (6) the use of combinations of the radiopaque microparticles and radiopaque iodinated polymers of items 1 & 2 for the production of medical devices and the pharmaceutical products described in items 3-5. Further illustrations of the present invention are provided by the following examples:
- L-lactide (0.5901 mol 85.0 grams, 82% by mol), glycolide (0.1295 mol 15.0 grams, 18% by mol), and 3-iodo-1-propanol (0.01799 mol 3.346 grams) were added to a flame-dried reaction flask fitted with a stainless steel stir rod. Low pressure (0.1-0.5 mmHg) was applied to the reaction setup for 30 minutes to 1 hour while heating in a silicone oil bath at 40° C. The system was purged with nitrogen gas, a stirrer bearing was attached to the mechanical stirrer, and the temperature of the system was raised to 140° C. to melt the monomer while stirring under a nitrogen atmosphere. Following the complete mixing of molten lactide and glycolide monomers with an initiator at high temperature, the temperature was reduced to 100° C. Subsequently, tin-2- ethylhexanoate (6×10−5 mol, 0.2 molar in toluene) was added at 100° C., and the reaction was mixed thoroughly before increasing the temperature to 135° C. to begin polymerization. The reaction was stirred for approximately 4.5 hours at 130-135° C., followed by continued polymerization at 135° C. for 60-70 hours without stirring. The reaction flask contents were allowed to cool to room temperature and the polymer was isolated. Samples of the isolated polymer were analyzed for molecular weight, identity, and thermal properties using standard GPC, IR, and DSC protocols, respectively.
- L-lactide (0.5901 mol, 85.0 grams, 82% by mol), glycolide (0.1295 mol, 15.0 grams, 18% by mol), and 3-iodo-1-propanol (0.01439 mol, 2.677 grams) were added to a flame-dried reaction flask fitted with a stainless steel stir rod. Low pressure (0.1-0.5 mmHg) was applied to the reaction setup for 30 minutes to 1 hour while heating in a silicone oil bath at 40° C. The system was purged with nitrogen gas, a stirrer bearing was attached to the mechanical stirrer, and the temperature of the system was raised to 140° C. to melt the monomer while stirring under a nitrogen atmosphere. Following the complete mixing of molten lactide and glycolide monomers with initiator at high temperature, the temperature was reduced to 100° C. Subsequently, tin-2-ethylhexanoate (6×10−5 mol, 0.2 molar in toluene) was added at 100° C., and the reaction was mixed thoroughly before increasing the temperature to 135° C. to begin polymerization. The reaction was stirred for approximately 4.5 hours at 130-135° C., followed by continued polymerization at 135° C. for 60-70 hours without stirring. The reaction flask contents were allowed to cool to room temperature and the polymer was isolated. Samples of the isolated polymer were analyzed for molecular weight, identity, and thermal properties using standard GPC, IR, and DSC protocols, respectively.
- The radiopaque lactide/glycolide copolymer, initiated with 3-iodo-1-propanol (3.05×10−3 mol, 50.1 grams), was added to a flame-dried reaction kettle fitted with a mechanical stirrer, a distillation neck and a collection flask. The polymer was dissolved in dichloromethane (0.5 g/ml) and mixed thoroughly with the mechanical stirrer at room temperature. Then 1,6-diisocyanatohexane (I.527×10−3 moles, 0.257 grams) was added to the reaction (1 mole of 1,6-diisocyanatohexane per 2 moles polymer) and the temperature was increased to 150° C. for 1-2 hours to react and to distill off the solvent. Upon cooling to room temperature, the resulting linked polymer was dissolved in dichloromethane (25% wt/vol), and 5 milliliters of isopropyl alcohol was added to the solution to quench any unreacted 1,6 diisocyanatohexane. Subsequently, the solution was precipitated in chilled isopropyl alcohol and filtered. The purified polymer was then dried at room temperature and reduced pressure. Samples of the isolated polymer were isolated and analyzed for molecular weight, identity, and thermal properties using standard GPC, IR, and DSC protocols, respectively.
- Films were prepared by a solvent-casting technique by first dissolving PI-1 in a mixture of 1:1 dichloromethane:chloroform at a concentration of 5-w/v%. The polymer solution was transferred to a glass container to allow solvent evaporation, resulting in a film (PI-1F1) of 0.2 mm thickness.
- Preparation of Films from PI-1 containing 10% NaI was performed by dissolving 2.7 g PI-1 and 0.3 g NaI in 60 mL of trifluoroethanol. The dissolved solution was transferred to a glass container to allow solvent evaporation, resulting in a film (PI-1F2) of 0.2 mm thickness.
- Radiopacity of both films (PI-1F1 and PI-1F2) was verified using a Tingle model 325 M Veterinary X-ray unit with an EKLIN model EDR5-MKV processor.
- Electrospinning was accomplished on an electrospinning unit constructed in-house from a solution containing approximately 25-w/v% PI-1 in 1:1 dichloromethane:chloroform. Electrospinning was conducted using the following conditions: +5.6 kV charge at needle tip, −8.7 kV charge at collection rod, +5 kV at directional rings, 18 G blunt end needle, 0.25 mL/min flow rate, and 18 cm tip-to-collector distance. The electrospun fabric was comprised of microfibers having an average diameter of 5 micron.
- Although the present invention has been described in connection with the preferred embodiments, it is to be understood that modifications and variations may be utilized without departing from the principles and scope of the invention, as those skilled in the art will readily understand. Accordingly, such modifications may be practiced within the scope of the following claims. Moreover, Applicant hereby discloses all subranges of all ranges disclosed herein. These subranges are also useful in carrying out the present invention.
Claims (14)
1-21. (canceled)
22. A medical device comprising a radiopaque coating located on the medical device, the radiopaque coating comprising a radiopaque, iodinated, absorbable, crystalline, 80-100% aliphatic polymer.
23. The medical device of claim 22 , wherein the medical device is selected from the group consisting of an absorbable/disintegratable urinogenital stent, an absorbable endovascular stent, and an absorbable diagnostic device.
24. The medical device of claim 22 , wherein the medical device is a catheter.
25. The medical device of claim 22 , wherein the polymer comprises ester linkages.
26. The medical device of claim 22 , wherein the polymer comprises chemical linkages selected from the group consisting of an aliphatic carbonate, acyclic carbonate, cycloaliphatic urethane, acyclic aliphatic urethane, cycloaliphatic carbonate, aliphatic ether, and aliphatic anhydride.
27. The medical device of claim 22 , wherein the polymer has a molecular weight of at least 5 kDa and a heat of fusion exceeding 10 J/g.
28. A method of producing a radiopaque absorbable composite comprising:
forming an organic absorbable crystalline matrix from a halogen-hydroxylic initiator and at least one cyclic monomer;
dispersing a water soluble radiopaque halogen salt in the form of microparticles or nanoparticles into the organic absorbable crystalline matrix to provide a dispersion; and
forming a radiopaque absorbable composite from the dispersion.
29. The method of claim 28 , wherein the organic absorbable crystalline matrix comprises a material selected from the group consisting of thermoplastic polyester, polyether-ester, segmented copolyester, segmented polyether-ester, segmented polyester-urethane, and a polyether-ester urethane.
30. The method of claim 28 , wherein the water soluble radiopaque halogen salt comprises an iodide or bromide salt.
31. The method of claim 28 , wherein the radiopaque absorbable composite is formed into a controlled drug release system selected from the group consisting of implantable monofilaments, microspheres, solid-suspensions, and viscous polymeric liquids.
32. The method of claim 28 , wherein the radiopaque absorbable composite is included within a surgical suture, endovascular stent, perivascular wrap, hemostatic device, block device, retraction tape, or endovascular device for treating aneurysms.
33. The method of claim 28 , wherein the organic absorbable crystalline matrix comprises the reaction product of a hydroxy-terminated halogenated polyester and a diisocyanate selected from the group consisting of 1,6-hexane-diisocyanate 1,4-bis(methylene isocyanate) cyclohexane 1,6-cyclohexane diisocyanate, 1,4-tetramethylene diisocyanate, lysine diisocyanate, or combinations thereof.
34. The method of claim 28 , wherein the cyclic monomer is selected from the group consisting of 1-lactide, glycolide, trimethylene carbonate, p-dioxanone, 1,5-dioxepan-2-one, ε-caprolactone, a morpholinedione, and combinations thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/147,712 US20160243292A1 (en) | 2010-04-06 | 2016-05-05 | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/798,461 US8808357B2 (en) | 2010-04-06 | 2010-04-06 | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
US14/337,344 US9339547B2 (en) | 2010-04-06 | 2014-07-22 | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
US15/147,712 US20160243292A1 (en) | 2010-04-06 | 2016-05-05 | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/337,344 Continuation US9339547B2 (en) | 2010-04-06 | 2014-07-22 | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160243292A1 true US20160243292A1 (en) | 2016-08-25 |
Family
ID=44710553
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/798,461 Expired - Fee Related US8808357B2 (en) | 2010-04-06 | 2010-04-06 | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
US14/337,344 Active US9339547B2 (en) | 2010-04-06 | 2014-07-22 | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
US15/147,712 Abandoned US20160243292A1 (en) | 2010-04-06 | 2016-05-05 | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/798,461 Expired - Fee Related US8808357B2 (en) | 2010-04-06 | 2010-04-06 | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
US14/337,344 Active US9339547B2 (en) | 2010-04-06 | 2014-07-22 | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
Country Status (1)
Country | Link |
---|---|
US (3) | US8808357B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8808357B2 (en) * | 2010-04-06 | 2014-08-19 | Poly-Med, Inc. | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
EP3892322B1 (en) | 2013-08-28 | 2022-09-28 | Clearstream Technologies Limited | Apparatuses and methods for providing radiopaque medical balloons |
US20150290344A1 (en) * | 2014-04-11 | 2015-10-15 | Clemson University | Biodegradable polyester- and poly(ester amide) based x-ray imaging agents |
CN104188107B (en) * | 2014-07-30 | 2019-01-08 | 深圳市合元科技有限公司 | The baking-type smoking apparatus of controllable tobacco heating amount |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3361700A (en) * | 1965-04-26 | 1968-01-02 | Sterling Drug Inc | Iodinated esters and resin compositions containing same |
US3645955A (en) * | 1970-03-18 | 1972-02-29 | Scient Tube Products Inc | Plasticized radiopaque vinyl resin compositions |
US4250072A (en) * | 1979-05-18 | 1981-02-10 | Flynn Vincent J | Radiopaque polyurethane resin compositions |
US4283447A (en) * | 1979-05-18 | 1981-08-11 | Flynn Vincent J | Radiopaque polyurethane resin compositions |
US4656224A (en) * | 1985-04-29 | 1987-04-07 | The Dow Chemical Company | Radiopaque thermoset polymer |
US5319059A (en) * | 1991-04-12 | 1994-06-07 | Juliane Jeck | Plastic X-ray contrast material |
US5342605A (en) * | 1992-05-01 | 1994-08-30 | Sterling Winthrop Inc. | Polymeric X-ray compositions containing iodinated polymeric beads |
US5346981A (en) * | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5746998A (en) * | 1994-06-24 | 1998-05-05 | The General Hospital Corporation | Targeted co-polymers for radiographic imaging |
US5795922A (en) * | 1995-06-06 | 1998-08-18 | Clemson University | Bone cement composistion containing microencapsulated radiopacifier and method of making same |
US6174330B1 (en) * | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US6426145B1 (en) * | 1999-05-20 | 2002-07-30 | Scimed Life Systems, Inc. | Radiopaque compositions for visualization of medical devices |
US6475477B1 (en) * | 1997-11-07 | 2002-11-05 | Rutgers, The State University | Radio-opaque polymer biomaterials |
US20030120029A1 (en) * | 2000-10-27 | 2003-06-26 | Shalaby Shalaby W. | Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom |
US20040054372A1 (en) * | 1997-08-19 | 2004-03-18 | Btg International Limited | Biodegradable composites |
US20050036946A1 (en) * | 2003-08-11 | 2005-02-17 | Pathak Chandrashekhar P. | Radio-opaque compounds, compositions containing same and methods of their synthesis and use |
US20060020331A1 (en) * | 2002-07-12 | 2006-01-26 | Cook Incorporated | Coated medical device |
US20060222860A1 (en) * | 2005-04-05 | 2006-10-05 | Basheer Rafil A | Radiopaque polymers for circuit board assembly |
US20070207186A1 (en) * | 2006-03-04 | 2007-09-06 | Scanlon John J | Tear and abrasion resistant expanded material and reinforcement |
US7465489B2 (en) * | 2005-11-15 | 2008-12-16 | Poly-Med, Inc. | Inorganic-organic melted-extruded hybrid filaments and medical applications thereof |
US20110245912A1 (en) * | 2010-04-06 | 2011-10-06 | Shalaby Shalaby W | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
US8361453B2 (en) * | 2006-06-06 | 2013-01-29 | Rutgers, The State University Of New Jersey | Iodinated polymers |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1006171A3 (en) * | 1992-09-07 | 1994-05-31 | Liegeois Jean Marie | Suits homogeneous material, flexible or rigid or adhesives moldable under the influence of a lower temperature 90 degrees c. |
US5415546A (en) * | 1993-03-23 | 1995-05-16 | Cox, Sr.; Ronald W. | Radiopaque dental composite and materials |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5731402A (en) * | 1995-04-25 | 1998-03-24 | Tokuyama Corporation | Biodegradable aliphatic polyester, melt-extrusion film thereof, and process for the production thereof |
US6013340A (en) * | 1995-06-07 | 2000-01-11 | Nike, Inc. | Membranes of polyurethane based materials including polyester polyols |
EP0905292B1 (en) * | 1996-05-14 | 2004-10-20 | Kanebo Ltd. | Spontaneously degradable fibers |
US6013855A (en) * | 1996-08-06 | 2000-01-11 | United States Surgical | Grafting of biocompatible hydrophilic polymers onto inorganic and metal surfaces |
JP2002524108A (en) * | 1998-07-28 | 2002-08-06 | インナーダイン, インコーポレイテッド | Absorbable brachytherapy and chemotherapy delivery devices and methods |
US6811776B2 (en) * | 2000-12-27 | 2004-11-02 | The Regents Of The University Of Michigan | Process for ex vivo formation of mammalian bone and uses thereof |
US6355058B1 (en) * | 1999-12-30 | 2002-03-12 | Advanced Cardiovascular Systems, Inc. | Stent with radiopaque coating consisting of particles in a binder |
US6444217B1 (en) * | 2000-04-25 | 2002-09-03 | University Of Washington | Drug delivery devices, and methods of use |
KR100448170B1 (en) * | 2001-06-23 | 2004-09-10 | 주식회사 태평양 | Amphiphilic biodegradable block copolymers comprising polyethylenimine(PEI) as a hydrophilic block and polyester as a hydrophobic block, and self-assembled polymer aggregates in aqueous milieu formed from the block copolymers |
US6861503B2 (en) * | 2002-02-27 | 2005-03-01 | Poly-Med, Inc. | Interlinked solid polyethylene glycols and copolymers thereof |
US7026374B2 (en) * | 2002-06-25 | 2006-04-11 | Aruna Nathan | Injectable microdispersions for medical applications |
US7101566B2 (en) * | 2002-06-28 | 2006-09-05 | Ethicon, Inc. | Polymer coated microparticles for sustained release |
FI20021570A0 (en) * | 2002-09-03 | 2002-09-03 | Gallen Kallela Siren Janne | Improved structure of coated surgical stent |
CA2575740A1 (en) * | 2004-03-24 | 2005-10-13 | Doctor's Research Group, Inc. | Methods of performing medical procedures that promote bone growth, methods of making compositions that promote bone growth, and apparatus for use in such methods |
US20050287216A1 (en) * | 2004-06-29 | 2005-12-29 | Loomis Gary L | Medical imaging agents for injectable compositions |
US8083806B2 (en) * | 2005-02-04 | 2011-12-27 | Poly-Med, Inc. | Radiation and radiochemically sterilized fiber-reinforced, composite urinogenital stents |
CA2623565A1 (en) * | 2005-09-28 | 2007-04-05 | Biovascular, Inc. | Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation |
EP1988847B1 (en) * | 2006-02-08 | 2014-08-13 | Northwestern University | Functionalizing implantable devices with a poly (diol-co-citrate) polymer |
WO2010033640A1 (en) * | 2008-09-16 | 2010-03-25 | Rutgers, The State University Of New Jersey | Bioresorbable polymers synthesized from monomer analogs of natural metabolites |
KR100845629B1 (en) * | 2007-01-03 | 2008-07-10 | 에스케이씨 주식회사 | Multilayered aliphatic polyester film |
AU2008206953A1 (en) * | 2007-01-19 | 2008-07-24 | Cinvention Ag | Porous, non-degradable implant made by powder molding |
WO2008122595A2 (en) * | 2007-04-05 | 2008-10-16 | Cinvention Ag | Biodegradable therapeutic implant for bone or cartilage repair |
US20080269874A1 (en) * | 2007-04-30 | 2008-10-30 | Yunbing Wang | Implantable medical devices fabricated from polymers with radiopaque groups |
EP2197394B1 (en) * | 2007-08-31 | 2013-03-27 | Cook Medical Technologies LLC | Medical implant having improved drug eluting features |
US20090306120A1 (en) * | 2007-10-23 | 2009-12-10 | Florencia Lim | Terpolymers containing lactide and glycolide |
US20110104052A1 (en) * | 2007-12-03 | 2011-05-05 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
US7935143B2 (en) * | 2008-01-02 | 2011-05-03 | Abbott Cardiovascular Systems Inc. | Stent formed from polymer-bioceramic composite with radiopaque bioceramic particles |
US20090233887A1 (en) * | 2008-03-12 | 2009-09-17 | Shalaby Shalaby W | Hydroswellable, Segmented, Aliphatic Polyurethanes and Polyurethane Ureas |
US9259515B2 (en) * | 2008-04-10 | 2016-02-16 | Abbott Cardiovascular Systems Inc. | Implantable medical devices fabricated from polyurethanes with grafted radiopaque groups |
JP5694940B2 (en) * | 2008-10-11 | 2015-04-01 | ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー | Phase separated biocompatible polymer composition for medical use |
US20100303878A1 (en) * | 2009-06-02 | 2010-12-02 | Joram Slager | Biodegradable bioactive agent releasing matrices with particulates |
US8586731B2 (en) * | 2009-06-11 | 2013-11-19 | Surmodics, Inc. | Hydrophobic polysaccharides with diester- or carbonate ester-containing linkages having enhanced degradation |
EP2459617A4 (en) * | 2009-07-31 | 2016-06-08 | Univ Rutgers | Bioresorbable polymers synthesized from monomer analogs of natural metabolites |
WO2011041517A1 (en) * | 2009-09-30 | 2011-04-07 | Surmodics, Inc. | Hydrophobic polysaccharides with silyl ether linkages having enhanced degradation and medical articles made therefrom |
CA3029961C (en) * | 2009-10-11 | 2021-06-22 | Rutgers, The State Of University Of New Jersey | Biocompatible polymers for medical devices |
US8568760B2 (en) * | 2009-12-30 | 2013-10-29 | Surmodics, Inc. | Hydrophobic polysaccharides with pendent groups having terminal reactive functionalities and medical uses thereof |
CA2807153C (en) * | 2010-08-06 | 2019-07-09 | Endoshape, Inc. | Radiopaque shape memory polymers for medical devices |
-
2010
- 2010-04-06 US US12/798,461 patent/US8808357B2/en not_active Expired - Fee Related
-
2014
- 2014-07-22 US US14/337,344 patent/US9339547B2/en active Active
-
2016
- 2016-05-05 US US15/147,712 patent/US20160243292A1/en not_active Abandoned
Patent Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3361700A (en) * | 1965-04-26 | 1968-01-02 | Sterling Drug Inc | Iodinated esters and resin compositions containing same |
US3645955A (en) * | 1970-03-18 | 1972-02-29 | Scient Tube Products Inc | Plasticized radiopaque vinyl resin compositions |
US4250072A (en) * | 1979-05-18 | 1981-02-10 | Flynn Vincent J | Radiopaque polyurethane resin compositions |
US4283447A (en) * | 1979-05-18 | 1981-08-11 | Flynn Vincent J | Radiopaque polyurethane resin compositions |
US4656224A (en) * | 1985-04-29 | 1987-04-07 | The Dow Chemical Company | Radiopaque thermoset polymer |
US5319059A (en) * | 1991-04-12 | 1994-06-07 | Juliane Jeck | Plastic X-ray contrast material |
US5342605A (en) * | 1992-05-01 | 1994-08-30 | Sterling Winthrop Inc. | Polymeric X-ray compositions containing iodinated polymeric beads |
US5346981A (en) * | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5746998A (en) * | 1994-06-24 | 1998-05-05 | The General Hospital Corporation | Targeted co-polymers for radiographic imaging |
US5795922A (en) * | 1995-06-06 | 1998-08-18 | Clemson University | Bone cement composistion containing microencapsulated radiopacifier and method of making same |
US6174330B1 (en) * | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US20040054372A1 (en) * | 1997-08-19 | 2004-03-18 | Btg International Limited | Biodegradable composites |
US6475477B1 (en) * | 1997-11-07 | 2002-11-05 | Rutgers, The State University | Radio-opaque polymer biomaterials |
US6426145B1 (en) * | 1999-05-20 | 2002-07-30 | Scimed Life Systems, Inc. | Radiopaque compositions for visualization of medical devices |
US20030120029A1 (en) * | 2000-10-27 | 2003-06-26 | Shalaby Shalaby W. | Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom |
US20060020331A1 (en) * | 2002-07-12 | 2006-01-26 | Cook Incorporated | Coated medical device |
US20050036946A1 (en) * | 2003-08-11 | 2005-02-17 | Pathak Chandrashekhar P. | Radio-opaque compounds, compositions containing same and methods of their synthesis and use |
US20060222860A1 (en) * | 2005-04-05 | 2006-10-05 | Basheer Rafil A | Radiopaque polymers for circuit board assembly |
US7790814B2 (en) * | 2005-04-05 | 2010-09-07 | Delphi Technologies, Inc. | Radiopaque polymers for circuit board assembly |
US7465489B2 (en) * | 2005-11-15 | 2008-12-16 | Poly-Med, Inc. | Inorganic-organic melted-extruded hybrid filaments and medical applications thereof |
US20070207186A1 (en) * | 2006-03-04 | 2007-09-06 | Scanlon John J | Tear and abrasion resistant expanded material and reinforcement |
US8361453B2 (en) * | 2006-06-06 | 2013-01-29 | Rutgers, The State University Of New Jersey | Iodinated polymers |
US20110245912A1 (en) * | 2010-04-06 | 2011-10-06 | Shalaby Shalaby W | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
US8808357B2 (en) * | 2010-04-06 | 2014-08-19 | Poly-Med, Inc. | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
US9339547B2 (en) * | 2010-04-06 | 2016-05-17 | Poly-Med, Inc. | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof |
Also Published As
Publication number | Publication date |
---|---|
US20110245912A1 (en) | 2011-10-06 |
US9339547B2 (en) | 2016-05-17 |
US8808357B2 (en) | 2014-08-19 |
US20140336277A1 (en) | 2014-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7632765B2 (en) | Inorganic-organic melt-extruded hybrid yarns and fibrous composite medical devices thereof | |
US11878087B2 (en) | Oriented implants containing poly(butylene succinate) and copolymer, and methods of use thereof | |
US4429080A (en) | Synthetic copolymer surgical articles and method of manufacturing the same | |
US7465489B2 (en) | Inorganic-organic melted-extruded hybrid filaments and medical applications thereof | |
US9339547B2 (en) | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof | |
US9044524B2 (en) | Absorbable polyethylene diglycolate copolymers to reduce microbial adhesion to medical devices and implants | |
US7968656B2 (en) | Absorbable copolyesters of poly(ethoxyethylene diglycolate) and glycolide | |
CN109464168A (en) | Plugging device | |
Guo et al. | Preparation of doxorubicin loaded Poly (ethylene glycol)-Poly (ε-caprolactone)-hydroxyapatite fibres as drug delivery systems | |
Wang et al. | Development of X-ray opaque poly (lactic acid) end-capped by triiodobenzoic acid towards non-invasive micro-CT imaging biodegradable embolic microspheres | |
CN101007868B (en) | Preparation method of biodegradable nano micelle controlled release formulation | |
AU2014342970A1 (en) | Absorbable poly (p-dioxanone-co-glycolide) monofilament fibers possessing mid-term strength retention post-implantation | |
Guidotti et al. | Micro/nanoparticles fabricated with triblock PLLA-based copolymers containing PEG-like subunit for controlled drug release: Effect of chemical structure and molecular architecture on drug release profile | |
JP3487703B2 (en) | Bioabsorbable polyester and method for producing the same | |
CN112469550B (en) | Absorbable copolymer compositions for high strength sutures with enhanced post-implantation strength retention | |
US8579939B2 (en) | Silk / absorbable polyester hybrid medical devices and applications thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |